|
Sep 30
|
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
|
|
Jul 30
|
InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
|
Jun 10
|
InMed to Present at the Emerging Growth Conference
|
|
Mar 20
|
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
|
|
Feb 9
|
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
|
|
Jan 16
|
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
|
|
Dec 19
|
InMed Announces Results of 2023 Annual General Meeting
|
|
Nov 29
|
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
|
|
Nov 2
|
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
|